Viewing Study NCT06393751


Ignite Creation Date: 2025-12-24 @ 11:42 PM
Ignite Modification Date: 2025-12-25 @ 9:34 PM
Study NCT ID: NCT06393751
Status: WITHDRAWN
Last Update Posted: 2025-06-03
First Post: 2024-04-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
Sponsor: National Cancer Institute (NCI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module